These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 28899685)
1. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy. Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685 [TBL] [Abstract][Full Text] [Related]
2. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways. Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421 [TBL] [Abstract][Full Text] [Related]
3. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768 [TBL] [Abstract][Full Text] [Related]
4. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy. Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167 [TBL] [Abstract][Full Text] [Related]
5. BET inhibitor suppresses melanoma progression Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224 [No Abstract] [Full Text] [Related]
6. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas. Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423 [TBL] [Abstract][Full Text] [Related]
7. miR-579-3p controls melanoma progression and resistance to target therapy. Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895 [TBL] [Abstract][Full Text] [Related]
8. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159 [TBL] [Abstract][Full Text] [Related]
10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
11. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression. Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326 [TBL] [Abstract][Full Text] [Related]
12. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559 [TBL] [Abstract][Full Text] [Related]
14. Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways. Yi C; Zhang Y; Yu Z; Xiao Y; Wang J; Qiu H; Yu W; Tang R; Yuan Y; Guo W; Deng W PLoS One; 2014; 9(7):e99943. PubMed ID: 25000190 [TBL] [Abstract][Full Text] [Related]
15. TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling. Che Y; Li Y; Zheng F; Zou K; Li Z; Chen M; Hu S; Tian C; Yu W; Guo W; Luo M; Deng W; Zou L Cancer Lett; 2019 Jun; 452():1-13. PubMed ID: 30905820 [TBL] [Abstract][Full Text] [Related]
16. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
17. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma. Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876 [No Abstract] [Full Text] [Related]